TY - JOUR
T1 - Endometrial cancer
AU - Makker, Vicky
AU - MacKay, Helen
AU - Ray-Coquard, Isabelle
AU - Levine, Douglas A.
AU - Westin, Shannon N.
AU - Aoki, Daisuke
AU - Oaknin, Ana
N1 - Funding Information:
Outside the submitted work, V.M. reports research (all funding to institution)/consultant/advisory board member support from Merck, Eisai, Karyopharm, AstraZeneca, Clovis, Moreo, Takeda, Zymeworks, Genentech, GSK, Dicephera and Faeth. D.A.L. has held consulting/advisory role for Tesaro/GSK, Merck, receives research funding to his institution from Merck, Tesaro, Clovis Oncology, Regeneron, Agenus, Takeda, Immunogen, VBL Therapeutics, Genentech, Celsion, Ambry and Splash Pharmaceuticals. D.A.L. is a founder of Nirova BioSense, Inc. D.A.L. is currently a full-time employee of Merck. I.R.-C. reports honoraria (self) from AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; honoraria (institution) from GSK, MSD, Roche and BMS; advisory/consulting fees from AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding (self) from MSD, Roche and BMS; research grant/funding (institution) from MSD, Roche, BMS, Novartis, AstraZeneca and Merck Sereno; and travel support from Roche, AstraZeneca and GSK. A.O. has served on advisory boards for Roche, AstraZeneca, PharmaMar, Clovis Oncology, Tesaro, Inmunogen, Genmab, Mersana Therapeutic, GSK and Deciphera Pharmaceutical and has received support for travel or accommodation from Roche, AstraZeneca and PharmaMar. H.M. has served on the advisory boards of Merck, Essai, GSK and AstraZeneca. D.A. has research grant support from Aska Pharmaceutical, Takeda and Tsumura; has served as consultant for AstraZeneca, Takeda, MSD, Myriad Genetics, AbbVie, Chugai and Ono; and has received honoraria from AbbVie, MSD, Aska Pharmaceutical, AstraZeneca, Takeda, Chugai, Ono, Taiho and Bayer. S.N.W. reports research support from ArQule, AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, GSK/Tesaro, Mereo, Novartis, Roche/Genentech and Zentalis; and has served as consultant for Agenus, AstraZeneca, Circulogene, Clovis Oncology, Eisai, EQRX, GSK/Tesaro, Lilly, Merck, Novartis, Pfizer, Roche/Genentech and Zentalis.
Funding Information:
V.M. is supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. S.N.W. is supported in part through the NIH/NCI Cancer Center Support Grant (NIH CA016672) and the NIH SPORE in Uterine Cancer (NIH 5P50CA098258-13).
Publisher Copyright:
© 2021, Springer Nature Limited.
PY - 2021/12
Y1 - 2021/12
N2 - Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.
AB - Although endometrial cancer management remains challenging, a deeper understanding of the genetic diversity as well as the drivers of the various pathogenic states of this disease has led to development of divergent management approaches in an effort to improve therapeutic precision in this complex malignancy. This comprehensive review provides an update on the epidemiology, pathophysiology, diagnosis and molecular classification, recent advancements in disease management, as well as important patient quality-of-life considerations and emerging developments in the rapidly evolving therapeutic landscape of endometrial cancers.
UR - http://www.scopus.com/inward/record.url?scp=85120938259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120938259&partnerID=8YFLogxK
U2 - 10.1038/s41572-021-00324-8
DO - 10.1038/s41572-021-00324-8
M3 - Review article
C2 - 34887451
AN - SCOPUS:85120938259
SN - 2056-676X
VL - 7
JO - Nature Reviews Disease Primers
JF - Nature Reviews Disease Primers
IS - 1
M1 - 88
ER -
